Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Flush With Cash, Tesaro Advances Rolapitant Toward NDA

This article was originally published in The Pink Sheet Daily

Executive Summary

Tesaro’s three-drug oncology program, including its lead NK-1 product for chemo-induced nausea and vomiting, is boosted by a recent raise from the public markets.

You may also be interested in...



Tesaro On Track For Mid-Year NDA Filing Of Oral CINV Candidate Rolapitant

While awaiting data from the third and final Phase III trial of the oral cancer supportive care candidate, Tesaro also will advance an I.V. formulation of rolapitant. Meanwhile, PARP inhibitor niraparib is in two Phase III trials in oncology indications, with a plan to seek other tumor types the compound might treat.

Tesaro’s Rolapitant Hits Primary Endpoints, But Still Disappoints

The oncology company’s nausea treatment was successful in late-stage trials, but Tesaro may have trouble differentiating the drug once it reaches the market due to a lack of evidence that it can compete with the current standard of care.

Tesaro’s Rolapitant Hits Primary Endpoints, But Still Disappoints

The oncology company’s nausea treatment was successful in late-stage trials, but Tesaro may have trouble differentiating the drug once it reaches the market due to a lack of evidence that it can compete with the current standard of care.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS075498

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel